A detailed history of Aqr Capital Management LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 195,963 shares of BBIO stock, worth $5.44 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
195,963
Previous 125,160 56.57%
Holding current value
$5.44 Million
Previous $3.17 Million 57.38%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.91 - $31.3 $1.69 Million - $2.22 Million
70,803 Added 56.57%
195,963 $4.99 Million
Q2 2024

Aug 14, 2024

SELL
$23.0 - $31.04 $110,400 - $148,992
-4,800 Reduced 3.69%
125,160 $3.17 Million
Q1 2024

May 15, 2024

BUY
$27.35 - $40.45 $2.65 Million - $3.92 Million
96,926 Added 293.41%
129,960 $4.02 Million
Q4 2023

Feb 14, 2024

BUY
$24.02 - $43.89 $260,184 - $475,416
10,832 Added 48.79%
33,034 $1.33 Million
Q3 2023

Nov 14, 2023

SELL
$16.89 - $35.01 $61,175 - $126,806
-3,622 Reduced 14.03%
22,202 $585,000
Q2 2023

Aug 14, 2023

BUY
$13.29 - $18.01 $343,200 - $465,090
25,824 New
25,824 $444,000
Q4 2021

Feb 14, 2022

SELL
$11.38 - $53.41 $178,495 - $837,735
-15,685 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$46.87 - $64.24 $371,069 - $508,588
7,917 Added 101.92%
15,685 $735,000
Q2 2021

Aug 16, 2021

SELL
$46.47 - $63.93 $470,369 - $647,099
-10,122 Reduced 56.58%
7,768 $474,000
Q1 2021

May 17, 2021

BUY
$55.47 - $72.35 $775,969 - $1.01 Million
13,989 Added 358.6%
17,890 $1.1 Million
Q4 2020

Feb 16, 2021

SELL
$38.38 - $71.11 $70,926 - $131,411
-1,848 Reduced 32.14%
3,901 $277,000
Q3 2020

Nov 16, 2020

SELL
$27.2 - $42.19 $1.11 Million - $1.73 Million
-40,976 Reduced 87.7%
5,749 $216,000
Q2 2020

Aug 17, 2020

BUY
$22.22 - $35.69 $1.04 Million - $1.67 Million
46,725 New
46,725 $1.52 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.12B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.